BRAF mutations in thyroid tumors from an ethnically diverse group

Hereditary Cancer in Clinical Practice

Volumn 10, Issue 1, 2012, Pages

  Schulten, Hans Juergen ^a   Salama, Sherine ^b   Al Mansouri, Zuhoor ^c   Alotibi, Reem ^a   Al Ghamdi, Khalid ^b   Al Hamour, Osman A ^c   Sayadi, Hassan ^c   Al Aradati, Hosam ^c   Al Johari, Adel ^b   Huwait, Etimad ^a   Gari, Mamdooh ^a   Al Qahtani, Mohammed H ^a   Al Maghrabi, Jaudah ^b,c  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b King Abdulaziz University   (Saudi Arabia)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

BRAF mutations; Deletion codon 599; Duplication codon 599; Family history; Follicular adenoma; MENA region; Thyroid carcinoma

Indexed keywords

THREONINE;

ADULT; ARTICLE; B RAF GENE; CANCER INVASION; CANCER STAGING; DISTANT METASTASIS; ETHNICITY; EXON; FAMILY HISTORY; FEMALE; FOLLICULAR ADENOMA; FOLLICULAR VARIANT PAPILLARY THYROID CARCINOMA; GENE; GENE DELETION; GENE DUPLICATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NODULAR GOITER; NON WELL DIFFERENTIATED THYROID CARCINOMA; PAPILLARY THYROID CARCINOMA MICROCARCINOMA; THYROID CANCER; THYROID NODULE; THYROID TUMOR; TUMOR VOLUME;

EID: 84865341218     PISSN: 17312302     EISSN: 18974287     Source Type: Journal    
DOI: 10.1186/1897-4287-10-10     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000, 89:202-217. 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-A, 10897019.
3. Ministry of Health: Riyadh (KSA) Annual Cancer Incidence Report, Saudi Arabia , , http://www.scr.org.sa/index.php?lang=ar; http://www.scr.org.sa/reports/SCR2007.pdf, Ministry of Health: Riyadh (KSA).
4. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16:17-44. 2829440, 18987168.
5. Qari FA. Pattern of thyroid malignancy at a University Hospital in Western Saudi Arabia. Saudi Med J 2004, 25:866-870.
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
7. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90:6373-6379. 10.1210/jc.2005-0987, 16174717.
8. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. 10.1016/S0092-8674(04)00215-6, 15035987.
9. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202:247-251. 10.1002/path.1511, 14743508.
10. Nucera C, Goldfarb M, Hodin R, Parangi S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009, 1795:152-161.
11. Thyroid. AJCC Cancer Staging Manual 2010, 87-96. Springer, New York, Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, 7.
12. DeLellis RA, Williams ED. Thyroid and parathyroid tumors. Pathology and genetics of tumours of endocrine organs (IARC WHO classification of tumours) 2004, 51-56. IARC Press, Lyons, DeLellis RA, Lloyd RV, Heitz PU, Eng C.
13. Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 2011, 31:4179-4183.
14. , , http://blast.ncbi.nlm.nih.gov/Blast.cgi.
15. Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008, 93:611-618. 10.1210/jc.2007-1717, 18000091.
16. Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et al. BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15:191-205. 10.1677/ERC-07-0212, 18310287.
17. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110:38-46. 10.1002/cncr.22754, 17520704.
18. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006, 13:455-464. 10.1677/erc.1.01086, 16728573.
19. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008, 68:618-634.
20. Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246:466-470. discussion 470-461, 10.1097/SLA.0b013e318148563d, 1959359, 17717450.
21. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404. 10.1210/jc.2003-030838, 14602780.
22. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45:818-821.
23. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93:3943-3949. 10.1210/jc.2008-0607, 18682506.
24. Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090. 10.1210/jc.2007-1179, 17785355.
25. So YK, Son YI, Park JY, Baek CH, Jeong HS, Chung MK. Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg 2011, 145:422-427. 10.1177/0194599811404649, 21750338.
26. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88:4393-4397. 10.1210/jc.2003-030305, 12970315.
27. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63:588-593.
28. Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, Morandi L, Tallini G, Vanni R. Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab 2008, 93:177-181.
29. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:213-220. 10.1210/jc.2005-1336, 16219715.
30. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005, 446:589-595. 10.1007/s00428-005-1236-0, 15902486.
31. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7:569-580. 10.1038/nrendo.2011.142, 21878896.
32. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684. 10.1200/JCO.2008.18.2717, 2668972, 19255327.
33. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A. BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology 2011, 43:447-452. 10.1097/PAT.0b013e3283486178, 21716161.
34. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580. 10.1038/sj.onc.1206706, 12881714.
35. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004, 89:4267-4271. 10.1210/jc.2003-032224, 15356020.
36. Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010, 399:313-317. 10.1016/j.bbrc.2010.07.092, 20674547.
37. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28:2119-2123. 10.1038/onc.2009.73, 2685777, 19363522.
38. Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, et al. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011, 129:2297-2303. 10.1002/ijc.25893, 21190184.
39. Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006, 64:105-109.
40. Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, et al. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006, 25:4235-4240. 10.1038/sj.onc.1209448, 16501605.
41. Hou P, Liu D, Xing M. Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007, 6:377-379. 10.4161/cc.6.3.3818, 17297294.
42. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M, Basolo F. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008, 93:4398-4402. 10.1210/jc.2008-0887, 18697864.
43. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009, 20:122-126. 10.1007/s12022-009-9073-3, 19370421.